<SEC-DOCUMENT>0001213900-24-072251.txt : 20240823
<SEC-HEADER>0001213900-24-072251.hdr.sgml : 20240823
<ACCEPTANCE-DATETIME>20240823163536
ACCESSION NUMBER:		0001213900-24-072251
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240822
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240823
DATE AS OF CHANGE:		20240823

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		241236781

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea021219701-8k_arcabio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABIO="http://arcabio.com/20240822">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_ABIO_arcabio.com_20240822 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20240822_20240822 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000907654 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000004" name="dei:EntityCentralIndexKey">0000907654</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abio-20240822.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-22</xbrli:startDate>
        <xbrli:endDate>2024-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0; font-size: 10pt"></p>



<p style="margin: 0; font-size: 10pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 11pt"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></span><b><span style="font-size: 18pt"><br/>
</span>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20240822__20240822_zet7du36Oomd"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Date of Report (Date of earliest event reported): <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240822__20240822_znCMJbM9XqXj"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 22, 2024</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityRegistrantName_c20240822__20240822_zsiLkDoCd2d" style="font-size: 11pt"><b><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000011" name="dei:EntityRegistrantName">ARCA
biopharma, Inc</ix:nonNumeric></b></span><b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in Its
Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 36%"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20240822__20240822_z2tBSKAhCV4k"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 24%"><b><span id="xdx_901_edei--EntityFileNumber_c20240822__20240822_z5uftKstyZfg"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000013" name="dei:EntityFileNumber">000-22873</ix:nonNumeric></span></b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 38%"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20240822__20240822_z49aqzukt8Fh"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000014" name="dei:EntityTaxIdentificationNumber">36-3855489</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(State or Other Jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>of Incorporation)</b></p></td>
    <td>&#160;</td>
    <td style="text-align: center"><b>(Commission File Number)</b></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(IRS Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Identification No.)</b></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 47%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20240822__20240822_zYaeC6RWMkI5"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000015" name="dei:EntityAddressAddressLine1">10170 Church Ranch
    Way</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine2_c20240822__20240822_z8WkmbzjZgV4"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 52%"/></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20240822__20240822_zHHe2DXrVq29"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000017" name="dei:EntityAddressCityOrTown">Westminster</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240822__20240822_zfjHq8WBCs6a"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span></b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20240822__20240822_zviM2FoLQWSf"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000019" name="dei:EntityAddressPostalZipCode">80021</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(Address of Principal Executive Offices)</b></td>
    <td>&#160;</td>
    <td style="text-align: center"><b>(Zip Code)</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Registrant&#8217;s Telephone Number, Including Area
    Code:</b>&#160;<span id="xdx_904_edei--CityAreaCode_c20240822__20240822_zWG1yxneiRkf"><b><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000020" name="dei:CityAreaCode">(720)</ix:nonNumeric> </b></span></span><b><span style="font-size: 10pt"><span id="xdx_90D_edei--LocalPhoneNumber_c20240822__20240822_zayg5ra1dpgg"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000021" name="dei:LocalPhoneNumber">940-2100</ix:nonNumeric></span></span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--WrittenCommunications_c20240822__20240822_zq5YbD0GN2O9"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--SolicitingMaterial_c20240822__20240822_ztSCYHYw5FW1"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--PreCommencementTenderOffer_c20240822__20240822_zAmJL57kUHo2"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20240822__20240822_zE2RSRmCfQ58"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><br/>
<b>Title of each class</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 30%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange
on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20240822__20240822_zG9YEpmAXrN4"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000026" name="dei:Security12bTitle">Common</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20240822__20240822_zYmuRGYg2PS4"><ix:nonNumeric contextRef="AsOf2024-08-22" id="Fact000027" name="dei:TradingSymbol">ABIO</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20240822__20240822_ziUnS988qB3"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20240822__20240822_zZRqc2iTlwa5"><ix:nonNumeric contextRef="AsOf2024-08-22" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously disclosed, on April 3, 2024, ARCA biopharma, Inc., a
Delaware corporation (&#8220;<span style="text-decoration: underline">ARCA</span>&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;<span style="text-decoration: underline">Merger
Agreement</span>&#8221;) pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in
the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (&#8220;<span style="text-decoration: underline">First Merger Sub</span>&#8221;),
will merge with and into Oruka Therapeutics, Inc. (&#8220;<span style="text-decoration: underline">Oruka</span>&#8221;), with Oruka continuing as a wholly owned subsidiary of
ARCA and the surviving corporation of the merger (the &#8220;<span style="text-decoration: underline">First Merger</span>&#8221;), and Oruka will merge with and into Atlas Merger
Sub&#160;II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (&#8220;<span style="text-decoration: underline">Second Merger Sub</span>&#8221; and
together with First Merger Sub, &#8220;<span style="text-decoration: underline">Merger Subs</span>&#8221;), with Second Merger Sub being the surviving entity of the merger (the
&#8220;<span style="text-decoration: underline">Second Merger</span>&#8221; and, together with the First Merger, the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.07 Submission of Matters to a Vote of Security Holders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, ARCA held a special meeting of its stockholders
on August 22, 2024 (the &#8220;<span style="text-decoration: underline">Special Meeting</span>&#8221;), at which ARCA&#8217;s stockholders voted on the proposals set forth below
relating to the Merger Agreement. The proposals are described in detail in ARCA&#8217;s definitive proxy statement/prospectus filed with
the U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) on July 22, 2024 and declared effective by the SEC on July
24, 2024 (the &#8220;<span style="text-decoration: underline">Definitive Proxy Statement/Prospectus</span>&#8221;). The final voting results regarding each proposal are set forth
below. There were 14,507,143 shares of ARCA common stock, par value $0.001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;), issued and
outstanding and entitled to vote on July 22, 2024, the record date for the Special Meeting, 9,795,459 shares of ARCA common stock were
represented in person or by proxy at the Special Meeting, which number constituted a quorum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Proposal
No. 1. Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion
of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately
prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex&#160;A
to the Proxy Statement/Prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules
5635(a)&#160;and 5635(b), respectively</i></span><i><b>.</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><b>&#160;</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">For</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Against</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Abstain</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Broker Non-Votes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 23%; font-size: 10pt; text-align: center">9,375,442</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">41,765</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">3,690</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">374,562</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 2. Approve an amendment to the amended and restated
certificate of incorporation of ARCA (the &#8220;<span style="text-decoration: underline">ARCA Charter</span>&#8221;) to increase the number of shares of ARCA common stock that
ARCA is authorized to issue from 100,000,000 shares to 545,000,000 (the &#8220;<span style="text-decoration: underline">Authorized Share Increase Amendment</span>&#8221;), in
the form attached as Annex&#160;G to the Proxy Statement/Prospectus. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">For</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Against</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Abstain</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Broker Non-Votes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 23%; font-size: 10pt; text-align: center">9,353,818</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">64,105</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">2,974</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">374,562</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 3. Approve an amendment to the ARCA Charter to effect
a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the
form attached as Annex&#160;H to the Proxy Statement/Prospectus (the &#8220;<span style="text-decoration: underline">Reverse Stock Split Amendment</span>&#8221;), if deemed necessary
by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed
by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if Proposal 1 is not approved
by ARCA stockholders, determined solely by ARCA&#8217;s board of directors.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">For</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Against</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Abstain</td><td style="font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt; font-weight: bold">Broker Non-Votes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 23%; font-size: 10pt; text-align: center">9,729,049</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">64,009</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">2,401</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 10pt; text-align: center">0</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 4. Approve an amendment to the ARCA Charter to reflect
Delaware law provisions regarding officer exculpation, in the form attached as Annex&#160;I to the Proxy Statement/Prospectus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of the Company&#8217;s
stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Against</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Abstain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: center">8,382,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">1,027,657</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">10,595</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">374,562</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 5. Elect the Class&#160;III director, Jacob Ma-Weaver,
to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has
been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval
of this Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board
of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Withheld</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: center">8,123,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: center">1,296,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 30%; text-align: center">374,562</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 6. Ratify the appointment of KPMG LLP as ARCA&#8217;s
independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP
is expected to be appointed for that fiscal year if the Merger is completed.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Against</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Abstain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: center">9,781,878</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">11,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">2,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 7. Approve the Oruka Therapeutics, Inc. 2024 Stock
Incentive Plan (the &#8220;<span style="text-decoration: underline">Oruka 2024 Incentive Plan</span>&#8221;), which will become effective as of and contingent on the completion
of the Merger.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Against</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Abstain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: center">7,060,386</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">2,338,980</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">21,531</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">374,562</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 8. Approve the Oruka Therapeutics, Inc. 2024 Employee
Stock Purchase Plan (the &#8220;<span style="text-decoration: underline">Oruka ESPP</span>&#8221; and together with the Oruka 2024 Incentive Plan, the &#8220;<span style="text-decoration: underline">Plans</span>&#8221;),
which will become effective as of and contingent on the completion of the Merger.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Against</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Abstain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: center">7,092,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">2,307,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">20,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">374,562</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 9. Approve, on an advisory basis, certain compensation
arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of ARCA&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">For</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Against</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Abstain</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Broker Non-Votes</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: center">9,321,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">91,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">8,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center">374,562</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Proposal No. 10. Approve an adjournment of the ARCA special meeting,
if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, Proposal No. 2 and/or Proposal
No. 3.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As there were sufficient votes to approve Proposal No. 1, Proposal
No. 2 and Proposal No. 3 at the time of the Special Meeting, Proposal No. 10 was not presented to stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following receipt of stockholder approval of all stockholder proposals
at the Special Meeting, and as previously disclosed, the Merger is expected to be consummated on August 29, 2024, subject to the satisfaction
of the remaining closing conditions under the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following approval of the Reverse Stock Split Amendment at the Special
Meeting, on August 22, 2024, the ARCA Board of Directors approved the reverse stock split at a ratio of 1-for-12 shares of Common Stock
(the &#8220;<span style="text-decoration: underline">Reverse Stock Split</span>&#8221;). ARCA expects to file the Reverse Stock Split Amendment with the Secretary of State of
the State of Delaware to effect the Reverse Stock Split, whereby every 12 shares of ARCA&#8217;s issued and outstanding Common Stock will
be converted automatically into one issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized
shares of Common Stock, and without any change in the par value per share. <span style="background-color: white">In addition, at the Special
Meeting, ARCA&#8217;s stockholders approved an increase in the number of shares of ARCA&#8217;s authorized common stock from 100,000,000
shares to 545,000,000 shares in connection with the anticipated closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the consummation of the Merger and the Reverse Stock Split
Amendment, ARCA will operate under the name, Oruka Therapeutics, Inc., and its shares are expected to begin trading on The Nasdaq Global
Market on a post-Reverse Stock Split and post-Merger basis under the ticker symbol &#8220;ORKA&#8221; effective with the open of business
on Tuesday, September 3, 2024. A new CUSIP number (687604108) and ISIN Number (US6876041087) will be assigned to the Common Stock as a
result of the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When the Reverse Stock Split is effective, every twelve
(12)&#160;shares of Common Stock issued and outstanding or held as treasury stock will be automatically combined and reclassified
into one share of Common Stock. In addition, as a result of the Reverse Stock Split, proportionate adjustments will made to the
exercise prices and number of shares of ARCA&#8217;s common stock underlying ARCA&#8217;s outstanding equity and warrant awards, and
to the number of shares of common stock issuable or will be issuable upon conversion of ARCA&#8217;s convertible preferred stock,
including ARCA&#8217;s Series B non-voting convertible preferred stock, par value $0.001 per share, to be issued in connection with
the Merger.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 23, 2024, ARCA issued a press release announcing approval
of the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on&#160;Form&#160;8-K&#160;and&#160;the exhibits
filed or furnished herewith contain forward-looking statements (including within the meaning of Section&#160;21E of the Securities Exchange
Act of 1934, as amended, and Section&#160;27A of the <span style="color: #212529; background-color: white">Securities Act of 1933, as
amended</span>) concerning ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements include express
or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company&#8217;s listing on
Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive
officers and directors of the combined company; each company&#8217;s and the combined company&#8217;s expected cash position at the closing
of the proposed Merger (including completion of Oruka&#8217;s private placement) and cash runway of the combined company; the expected
contribution and payment of dividends in connection with the Merger, including the timing thereof; the future operations of the combined
company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any
product candidates of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including
the expected timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates;
and other statements that are not historical fact. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives of these terms or variations of them) may identify
forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking
statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance
that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger will be those that have been
anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The forward-looking statements contained in this communication are
based on current expectations and beliefs concerning future developments and their potential effects and therefore subject to other risks
and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to satisfy
the conditions to the closing or consummation of the Merger, risks associated with the potential failure to complete the financing transaction
in a timely manner or at all, risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability
of each of ARCA and Oruka to consummate the transactions contemplated by the Merger, risks associated with ARCA&#8217;s continued listing
on Nasdaq until closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental
entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise
to the termination of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize
certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion
of the Merger on the combined company&#8217;s business relationships, operating results and business generally; risks associated with
the combined company&#8217;s ability to manage expenses and unanticipated spending and costs that could reduce the combined company&#8217;s
cash resources; risks related to the combined company&#8217;s ability to correctly estimate its operating expenses and other events; changes
in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue
to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the
combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby; the ability
of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates;
the combined company&#8217;s ability to advance the development of its product candidates or preclinical activities under the timelines
it anticipates in planned and future clinical trials; the combined company&#8217;s ability to replicate in later clinical trials positive
results found in preclinical studies and early-stage clinical trials of its product candidates; the combined company&#8217;s ability to
realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations;
regulatory requirements or developments and the combined company&#8217;s ability to obtain necessary approvals from the U.S. Food and
Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses
to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential
adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political
and economic developments; and those risks and uncertainties and other factors more fully described in filings with the Securities and
Exchange Commission (&#8220;<span style="text-decoration: underline">SEC</span>&#8221;), including reports filed on&#160;Form&#160;10-K,&#160;10-Q&#160;and&#160;8-K, in other
filings that ARCA makes and will make with the SEC&#160;in connection with the proposed Merger, including the Proxy Statement/Prospectus
described below under &#8220;Important Additional Information About the Proposed Transaction Filed with the SEC,&#8221; and&#160;in other
filings made by ARCA with the SEC from time to time and available at www.sec.gov. These forward-looking statements are based on current
expectations, and with regard to the proposed transaction, are based on ARCA&#8217;s current expectations, estimates and projections about
the expected date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management&#8217;s
beliefs and certain assumptions made by ARCA, all of which are subject to change. Such forward-looking statements are made as of the date
of this release, and the parties undertake no obligation to update such statements to reflect subsequent events or circumstances, except
as otherwise required by securities and other applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No Offer or Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K and the exhibits filed or furnished
herewith are not intended to and do not constitute (i)&#160;a solicitation of a proxy, consent or approval with respect to any securities
or in respect of the proposed transactions (the &#8220;<span style="text-decoration: underline">Proposed Transactions</span>&#8221;) between ARCA and Oruka or (ii)&#160;an offer
to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant
to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act
of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts
to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute
a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation,
facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange,
of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL
OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 11%"><b>Exhibit Number</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 88%"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.1</td>
    <td>&#160;</td>
    <td><a href="ea021219701ex99-1_arcabio.htm" style="-sec-extract: exhibit">Press Release, issued on August 23, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ARCA biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Registrant)</p>

</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 18%">&#160;</td>
    <td style="width: 33%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 40%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: August 23, 2024</td>
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">/s/ C. Jeffrey Dekker</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Name:</td>
    <td>C. Jeffrey Dekker</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>Chief Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">6</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUy3hPAxsYgsQiJ6XXKMJd2R2a3sk/rLNiUaBobh3nOvEBOxppVukOG8LAs4Yts1yiGUWCOjuaB3ZJttCv6WeNXWsTJueH9gRp5BzyShnCkvDNaHtlilEC2mUk7lHKJ5miRw2Ingq2dkal2hcVo1oEwFB6aONTrFrzHhqHoy1L6GqhOy1WRSiMNolN8go1jCnh7qSXyzUBSZCCbDBGLNdO+8K+8dmi8JeYOtr7Mj/d/gAwqDSpM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021219701ex99-1_arcabio.htm
<DESCRIPTION>PRESS RELEASE, ISSUED ON AUGUST 23, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ARCA biopharma
Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Westminster, CO</B>, August 23, 2024
&ndash; ARCA biopharma, Inc. (NASDAQ: ABIO) (&ldquo;ARCA&rdquo;) today announced that its Board of Directors (the &ldquo;Board&rdquo;)
has approved a reverse stock split of ARCA&rsquo;s common stock at a ratio of 1-for-12. ARCA&rsquo;s common stock is expected to begin
trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics,
Inc. and under the new symbol &ldquo;ORKA&rdquo; following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the &ldquo;Merger&rdquo;),
with a new CUSIP number 687604108 and ISIN number US6876041087.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The reverse stock split was approved
by ARCA&rsquo;s stockholders at ARCA&rsquo;s special meeting of stockholders held on August 22, 2024 (the &ldquo;Special Meeting&rdquo;),
to be effected in the Board&rsquo;s discretion of not less than 1-for-6 and not more than 1-for-12. The final reverse stock split ratio
of 1-for-12 was approved by the Board on August 22, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The reverse stock split is expected
to reduce the number of ARCA&rsquo;s outstanding common stock from approximately 14,507,143 shares to approximately 1,208,928 shares.
The number of shares of ARCA&rsquo;s authorized common stock will not be affected by the reverse stock split, but at the Special Meeting,
ARCA&rsquo;s stockholders approved an increase in the number of shares of ARCA&rsquo;s authorized common stock from 100,000,000 shares
to 545,000,000 shares in connection with the anticipated closing of the Merger. No fractional shares will be issued if, as a result of
the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of ARCA common
stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled
to receive a cash payment in lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which
such stockholder would otherwise be entitled multiplied by the closing price per share as reported by The Nasdaq Stock Market LLC on September
3, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">As a result of the reverse stock split,
proportionate adjustments will made to the exercise prices and number of shares of ARCA&rsquo;s common stock underlying ARCA&rsquo;s
outstanding equity and warrant awards, and will become effective as of and contingent on the completion of the Merger, and to the number
of shares of common stock issuable or will be issuable upon conversion of ARCA&rsquo;s convertible preferred stock, including ARCA&rsquo;s
Series B non-voting convertible preferred stock to be issued in connection with the Merger. There will be no change to the par value
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Following the closing of the Merger,
the combined company&rsquo;s total issued and outstanding common stock is expected to be approximately 29,490,443 shares, and there are
expected to be 5,430,360 shares of common stock underlying pre-funded warrants and 11,428,166 shares of common stock underlying ARCA&rsquo;s
Series B non-voting convertible preferred stock, representing a total of 46,348,969 common-stock equivalents (not including outstanding
employee and director equity awards).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About ARCA
biopharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">ARCA biopharma
is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach
to drug development. For more information, please visit&nbsp;<U>www.arcabio.com</U>&nbsp;or follow the company on LinkedIn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>About Oruka
Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Oruka Therapeutics
is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka&rsquo;s mission is to
offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving
high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio
of potentially&nbsp;best-in-class&nbsp;antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying
plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit&nbsp;<U>www.orukatx.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">This communication
contains forward-looking statements (including within the meaning of Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the
Securities Act) concerning ARCA, Oruka, the proposed transactions and other matters. These forward-looking statements include express
or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company&rsquo;s listing on
Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the expected executive
officers and directors of the combined company; each company&rsquo;s and the combined company&rsquo;s expected cash position at the closing
of the proposed Merger (including completion of Oruka&rsquo;s private placement) and cash runway of the combined company; the expected
contribution and payment of dividends in connection with the Merger, including the timing thereof; the future operations of the combined
company; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any
product candidates of the combined company; anticipated preclinical and clinical drug development activities and related timelines, including
the expected timing for data and other clinical results; the combined company having sufficient resources to advance its pipeline candidates;
and other statements that are not historical fact. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting ARCA, Oruka, including the pre-closing private financing, or the Merger
will be those that have been anticipated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">The forward-looking
statements contained in this communication are based on current expectations and beliefs concerning future developments and their potential
effects and therefore subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks
associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger risks associated with the
potential failure to complete the financing transaction in a timely manner or at all, risks associated with the uncertainty as to the
timing of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the transactions contemplated by the
Merger, risks associated with ARCA&rsquo;s continued listing on Nasdaq until closing of the Merger, the failure or delay in obtaining
required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; the occurrence of any event,
change or other circumstance or condition that could give rise to the termination of the Merger prior to the closing or consummation
of the Merger, risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect
to future financial and operating results; the effect of the completion of the Merger on the combined company&rsquo;s business relationships,
operating results and business generally; risks associated with the combined company&rsquo;s ability to manage expenses and unanticipated
spending and costs that could reduce the combined company&rsquo;s cash resources; risks related to the combined company&rsquo;s ability
to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability
of the combined company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs;
the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related
to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain and protect
its intellectual property rights, in particular those related to its product candidates; the combined company&rsquo;s ability to advance
the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical
trials; the combined company&rsquo;s ability to replicate in later clinical trials positive results found in preclinical studies and
early-stage clinical trials of its product candidates; the combined company&rsquo;s ability to realize the anticipated benefits of its
research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments
and the combined company&rsquo;s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory
authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in expected or
existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business
relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those risks
and uncertainties and other factors more fully described in filings with the Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;),
including reports filed on&nbsp;Form&nbsp;10-K,&nbsp;10-Q&nbsp;and&nbsp;8-K, in other filings that ARCA makes and will make with the
SEC&nbsp;in connection with the proposed Merger, including the Proxy Statement/Prospectus described below under &ldquo;Important Additional
Information About the Proposed Transaction Filed with the SEC,&rdquo; and&nbsp;in other filings made by ARCA with the SEC from time to
time and available at www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed
transaction, are based on ARCA&rsquo;s current expectations, estimates and projections about the expected date of closing of the proposed
transaction and the potential benefits thereof, its business and industry, management&rsquo;s beliefs and certain assumptions made by
ARCA, all of which are subject to change. Such forward-looking statements are made as of the date of this release, and the parties undertake
no obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required by securities and
other applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>No Offer
or Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">This communication
is not intended to and do not constitute (i)&nbsp;a solicitation of a proxy, consent or approval with respect to any securities or in
respect of the proposed transactions (the &ldquo;<U>Proposed Transactions</U>&rdquo;) between ARCA and Oruka or (ii)&nbsp;an offer to
sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to
the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act
of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts
to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute
a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation,
facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange,
of any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">NEITHER THE
SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL
OR COMPLETE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARCA biopharma Investor &amp; Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeff Dekker</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">720.940.2122</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@arcabio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Oruka Therapeutics Investor Relations Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alan Lada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">650.606.7911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Alan.lada@orukatx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>abio-20240822.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWayFiaPtzplyOZlBtmd8bclK7yUmlTPQLiILPoX2kZ8F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABIO="http://arcabio.com/20240822" elementFormDefault="qualified" targetNamespace="http://arcabio.com/20240822">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://arcabio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240822_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240822_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>abio-20240822_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>abio-20240822_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://arcabio.com/role/Cover" xlink:href="abio-20240822.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://arcabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139934079855328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 22,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA
biopharma, Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10170 Church Ranch
    Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westminster<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-2100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABIO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<[D9<P:=;D^ [U=2FK<=^^Y<_?0Q^0]02P,$%     @ <80769^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
M<807620>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ <80760=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !QA!=9K3-E
M5N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " !QA!=9F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '&$%UG;8!JO3@0   81
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " !QA!=9GZ ;\+$"  #B#   #0              @ &2#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '&$%UF7BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea021219701-8k_arcabio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcabio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abio-20240822.xsd</File>
    <File>abio-20240822_lab.xml</File>
    <File>abio-20240822_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea021219701-8k_arcabio.htm">ea021219701-8k_arcabio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea021219701-8k_arcabio.htm": {
   "nsprefix": "ABIO",
   "nsuri": "http://arcabio.com/20240822",
   "dts": {
    "schema": {
     "local": [
      "abio-20240822.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abio-20240822_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abio-20240822_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea021219701-8k_arcabio.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://arcabio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea021219701-8k_arcabio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea021219701-8k_arcabio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-24-072251-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-072251-xbrl.zip
M4$L#!!0    ( '&$%UE*GREU* ,  . +   1    86)I;RTR,#(T,#@R,BYX
M<V2U5L%RVC 0O7>F_Z#Z;@1VTQ "R21IZ3 A#0U)FLFE(VQ!-)$E1Y(#].LK
MV98#&%R@+2=I]=[;7>VN3/MT%E'PBH4DG'6<1JWN ,P"'A(VZ3AW0_=L>-'K
M.>#TY/T[H'_M#ZX+N@33L 4^\\#ML3$_!M]0A%O@*V98(,7%,;A'-#$6WB44
M"W#!HYABA?5!YJD%#FJ>CX#K;J%[CUG(Q=U-K]!]4BJ6+0BGTVF-\5<TY>)9
MU@(>;2<X5$@ELE"KS^KY;SOZ%9%!088O9P?R<'9#'B:8-9-+Y'^1/]"\2]!
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MITZ[IOO(0HR'BNE+:[1Z4[EC*Z%K6E(IO0Y:A,=8***;>>$)R$(GRM '"VZ
M\2,= /]AYA2-=LU<4S#]CRGWC7XYUS9<'BR]7QV^MDZ7"P58:8BKGM#L\>_S
M()6JH)B=:WFN,;D-S_4;M9D,WR+=)8BW&]@M",O;(X@-#_DZ_W(3W"Q,"_G;
M.MWP0:ATNI8#,5726O8.8?'S\1<QI#([!;%4SE ):"2,J.?J.OJ-S>'\B9GN
MY5Y-$/"$*3'?I1$6*7:S7S7>/OS;%<+BLR*8_P+[NMVC"\K.U[5 &V9J>OD;
M4$L#!!0    ( '&$%UF5C.U#_0H  ("&   5    86)I;RTR,#(T,#@R,E]L
M86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'$QLMD.QD%QE/LC VFV3CS&S;1;&@
M)<81(I,!)2?VOR\IBK)$\4A*BI*<BQF/^![JI?B8I+Z./_VXVZ3HA? L8?1L
M='ST<80(C5B<T/79Z.MR?+Z<+Q8CE.68QCAEE)R-*!O]^,.?_X3$GT_?C<?H
M,B%I?(J^L&B\H _L>W2--^04_40HX3AG_'OT#:=;N85=)BGA:,XVSRG)B2A0
M.SY%?S^:SC :CP?4^XW0F/&O=XNJWL<\?\Y.)Y/7U]<CRE[P*^-/V5'$-L,J
M7.8XWV95;1]W'\L_*OQ3FM"G4_G7"F<$B>-%L]-=EIR-Y'[+W;[.CAA?3Z8?
M/QY/_OG+U3)Z)!L\3J@\;A$9Z2A9BRWN^.3D9%*4:FE+N5OQ5.]C-M%VJII%
M:=*AKSG)DM.LL'?%(IP7W=Z[&P0JY/_&6C:6F\;'T_'L^&B7Q2-]\(LCR%E*
M[L@#*IIYFN^?!4I9(DD8E=L>.7FPFTDYG\CX"25KG)-8[NA$[NCX'W)'?RDW
M7^$524=(*@4?8+M.&G6501/79F\)3UA\0=_GVHSV9%]\=WC^/S2@'N^\"?<L
MQ^F[S-<CG=N^)N\[XH<X]T=:C//D?4>Z%OE_L9VW+;_Y\-J/:RHW7HE/#8MD
MEXL)C,3:I*RB8P0N]E!,#&7=5>TL:M2;RM&<\7;;Y<Q8U)F1Z&C-7B8Q243=
MTYG\,)8?BF:+__PQ9V(E<+[*<HZC7-=4-.-L9"F?F):D\IQK7YA'/8TK%9.(
MB:GI.1^GZC"J\ ?.-M;=EJUFEL(_TE45KPZ+V 5@M"'C)&-;'I$W]4K=+724
M2D>;5"CDDHK0\=?EZ(="@W[7JO]\FAQJ<=#18@FTW1":WXL:+2UH%KOJ9ILI
MW<OULB ZV6+([&,M05+CN(//Q8YCN?/+%*\M]HUR5UULM:7[N%$81"?;')F]
M7&F0%/GJYB\DBWCR+)?S7>UHR)QWNL5DJ^]KFK 0:!N#2:AI/0WL=V2=R*E%
M6I#GMT1N[!C& +WKH;_3MCD76,5!0#/$(3A;U(-0%>6)HW-*MSB](\^,=^'3
ME+FFQF;2A*6N"8H1BS$0#:5%2NR)B%^WXHR=\'3?"T5+Z9H+P*J)AB$+B@Z[
M-Q"02NZ7D7N.:9;( :P7DK;4^>D&8+9UZF'H@N($, >?DE1ZOZ0L'TF:ROL!
MF/8/*#:Q:UI@PR8O;650Q(#V0&:*"%2&A(/-Q8M<G8METL#&UO0^X6G9[N*G
M$@>+D.EP($5%&))QGDBJW8;H8:BE=$T/8-7DQI %18S=&\B*DJ-"[Q^2"QH/
M0J32^0'$L&G'HQ0%"$?361\:0NT3C,LDBW"JO%R*;5E'\RQ:UX" =DU(6L*@
M0('<@;"H ,U,$>(5F'\1S(?A4E/Z@:5EU8Y*)0L0%--;'R92[P62^9;SAFMX
MQH&ESF[*]IBM[L\"NB! Z3'7NFNKY U0/,U %S1/\KU\GNYZNUD1;FE<6^**
M#<B<9L(L#X(%P)3)@)(AJ4-*Z*7G]5T"FLN'&,'FF#*W!-A--BEH:@(BP6H,
MH.&@+9XI]4+$7(Q,'*<+&I/=SV0/MJNE<\L$8+,)A2$*B J[,P"+4HP*-1)R
M+V#<\F2#^7Z91#U315OH%@W(:),-4Q40'( U@(Y2C9:+N<^9Y![O%K$ -7E(
MU//@/92 >K>P]-AN,@.( T*GVR% D A"S2B?("UHQ/@SJSWN,&=;,0#NYRR&
M5R@]46ZA&M2$)EJ=(0$!-L0G@%DC](-Z)@4Q^1Y/40&2-7@A[CR.Q8'*RG^N
M$DJ.P?9;M6[IZK#;9,HB#(@DV!W 3ZG\H#\@&8-N:"C03-_0U*E_:*9#H9D&
M#<WT/=#<O[) H)F]H:DS_]#,AD(S"QJ:V;N@$1WO=:R9BX\W_)Z]VA[.!I5>
MD&E;M0)SD(6'2\M;'RPR0*YG9(A/3(J%U0V_Y>PEH1&\9(;D7H !3%NI,;3A
MH6,WV,=/M2#6<5['&K4H[_V2:)F?4:9ITC[$*$UXD#2-]0XN2NT3B5N6Y3C]
M=_+<>2)N%WO!PVK8"DE#&1XJ-GM]P*@8)()\G%B7N,H;&M97R8QR=Z\ 6VP=
M7@&N%08!@<U1^Q5@=?5$B5QWLV24$PR,",UB9YUL,57U<:TLC"YN&VKU</&]
M%AH?7V29W26]?604?D"@+7'5TY YW=MF>1 ]#I@R>[V0H4+GZ6J\S#"1V8?O
M6IFSF=VT4TWDNB"(WC7=M*9I7>ZX-W_C22[V/&>;S9:6=WELSPT".E>]W&E3
M][A5%$3O=SDS22BUJ"EVC,62I4F4Y E=_R)./GF";:VRB5P! 1O4-+050:
MVC(Y. B15CJ&X)83"2$1'5&\!"@3"_&;AP?K;-\E=@5%OV$-!ZP, I)>>R8L
M(F <U2*0"D%%C%]L%EFV)?Q-\%A"/"$$F@= :NE#Q DRV0N5"O3)UI)$6S$_
M[H^GJ_LD3VTGEVV)LSD),%?-2$9Y$&P IDP6BC+$'M#Q]*^KOR$=Y;C[K]D]
MQS)Y['*_6;$4R#YE5;F"H,.BYL B"0(%V)=)PS5#I10IK8_L5 VSEN88Y:X
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M[V4FPL8!S837VYF:OZ>M6KJMPJFR<9#,E:*&M]-]1C) T'$?5"\/Z#V*T[V
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ME,R(1J&\Y\B63*$TO]#%&LJ;;<DO#0L+_K#$I6/J;K*B=HLO>\/KF26CEUT
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M*FXTRD/1<%.ECU4?7..VM[S*M4T%;EO;>D0>@]R\<^!&VQOKKW)A#R*:8E(
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MR;FN7,+ - EOE#,W<RU]T(I R(:<B,,+&WJ<9,C,F1&V"]LZDV4/LY)YK,G
MC!]I<RS,FA@YHZ2$C;RN^/J(M_ <2)7GI$J1X+R\"(_2=8H"G*MJ.IF<4-VH
M6G\8\O@%^V#:/2H:T.T87T[P+&+11%I_/#'*@=.F7;/).7.,'OD4-O+[]_,W
MP6%TX6V>TD\$.C)BS16A2N4Y?JT=$Z :6)*_R.#LDJZ"0+NY%^J 8"3H]2+X
M0MDG,B<O2B>6.._U;%POWD[ZW";([2WS)CW&(I&78UVF3*OPUS*\!PN+T;UY
M^+%_@7ZCYCEWG/E^G:SB[-JMY>LZ% :\8QH3C&1*HF/8JLY\D@]0)DV^'""T
M3-3*<AL9\Z\0[<) U;N<&8< _$.AUX(4  HN@T72"?;45%UTRFKB2V]X#J[
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M:6\M,C R-# X,C(N>'-D4$L! A0#%     @ <807696,[4/]"@  @(8  !4
M             ( !5P,  &%B:6\M,C R-# X,C)?;&%B+GAM;%!+ 0(4 Q0
M   ( '&$%UG,/#;X50<  --7   5              "  8<.  !A8FEO+3(P
M,C0P.#(R7W!R92YX;6Q02P$"% ,4    " !QA!=9)#.VKATL  !0!@$ &@
M            @ $/%@  96$P,C$R,3DW,#$M.&M?87)C86)I;RYH=&U02P$"
M% ,4    " !QA!=9X5RZG[L4  !B4@  '0              @ %D0@  96$P
M,C$R,3DW,#%E>#DY+3%?87)C86)I;RYH=&U02P4&      4 !0!8 0  6E<
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ea021219701-8k_arcabio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abio-20240822.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-08-22</startDate>
            <endDate>2024-08-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-22" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-22" id="Fact000004">0000907654</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-22" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-22" id="Fact000010">2024-08-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-22" id="Fact000011">ARCA biopharma, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-22" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-22" id="Fact000013">000-22873</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-22" id="Fact000014">36-3855489</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-22" id="Fact000015">10170 Church Ranch     Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-22" id="Fact000016">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-22" id="Fact000017">Westminster</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-22" id="Fact000018">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-22" id="Fact000019">80021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-22" id="Fact000020">(720)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-22" id="Fact000021">940-2100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-08-22" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-22" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-22" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-22" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-22" id="Fact000026">Common</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-22" id="Fact000027">ABIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-22" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-22" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
